VANCOUVER, BC, Feb. 12, 2015 (GLOBE NEWSWIRE) -- via PRWEB - February 12, 2015 – Vancouver, BC – According to a new report published by iData Research (http://www.idataresearch.com), demand for bare-metal stents in Europe could decline dramatically if competing technologies, such as drug-eluting stents and drug-coated balloons provide cost-effective reductions in restenosis. Restenosis is the re-narrowing of treated blood vessel causing obstructions and decreased blood flow to vital organs. The restenosis rate following the use of bare-metal stents remains high, with re-occlusion occurring in up to 50% of cases.
"The European market for bare-metal stents is showing increasing signs of saturation, with intense competition leading to steep ASP declines," explains Dr. Kamran Zamanian, CEO of iData. "This trend has led the major companies in the field to pursue the commercialization of drug-eluting technology, including balloons and stents, which serve as a substitute for bare-metal stents."
Bare metal stents represent the largest peripheral stent segment in Europe, valued at over €166 million. By 2020, the bare metal stent market in Europe will represent slightly above 72% of the total peripheral stent market.
Other key findings from the latest edition of the iData Research report entitled European Markets for Peripheral Vascular Devices:
Clinical Trials
Clinical trials continue to play a central role in proving the efficacy of a particular treatment method and the superiority of a particular product. Recent clinical trials have supported the use of covered and drug-eluting stents. These results, and the release of longer-term data, will continue to drive demand for these products whose efficacy is established.
Price Erosion
Bare metal stents are increasingly perceived as commodities by purchasers. Current generation devices have all shown comparable results in achieving patency. As a result, prices continue to decrease significantly as companies attempt to increase market share. This trend will intensify as lower cost competing devices, such as drug-coated balloons, continue to be used in more procedures.
For Further Information
More on the markets for peripheral vascular devices in Europe can be found in this latest edition report published by iData entitled European Markets for Peripheral Vascular Devices, which covers 15 countries in Europe, as well as 500 market sub-segments by country for peripheral vascular stents, PTA balloon catheters, atherectomy devices, chronic total occlusion devices, embolic protection devices, stent-grafts, surgical grafts, AV access thrombectomy devices, inferior vena cava filters, diagnostic and interventional catheters, standard and hydrophilic guidewires, introducer sheaths, vascular closure devices, and transcatheter embolization devices.
The iData series on the market for peripheral vascular devices also covers the U.S., China, India, Japan, and 15 countries in Europe. Full reports provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players' success strategies in each market and segment.
Register online or email us at info(at)idataresearch(dot)net for a European Markets for Peripheral Vascular Devices report brochure and synopsis.
About Procedure Tracker
Procedure number data is available from iData's Procedure Tracker service, which allows subscribers to define and analyze procedure data segmented by state, region, hospital, surgery centre, and physician. A customizable dashboard sorts procedure data for further analysis and research.
About iData Research
iData Research (http://www.idataresearch.com) is an international market research and consulting group focused on providing market intelligence for medical device and pharmaceutical companies. iData covers research in: Diabetes Drugs, Diabetes Devices, Pharmaceuticals, Anesthesiology, Wound Management, Orthopedics, Cardiovascular, Ophthalmics, Endoscopy, Gynecology, Urology and more.
This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2015/02/prweb12513593.htm